1. Consoli U. Differential Induction of Apoptosis by Fludarabine Monophosphate in Leukemic B and Normal T Cells in Chronic Lymphocytic Leukemia. Blood 1998; 91 (5): 1742–8.
2. Hoffman R et al. Hematology: basic principles and practice. 3rd ed./Churchill Livingstone. 2000.
3. Redman J, Cabanillas F, Velasquez W et al. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 1992; 109: 790–4.
4. Keating M et al. Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial Therapy. Blood 1998; 92 (4): 1165–71.
5. French Cooperative Group on CLL, Johnson S, Smith A, Loffler H et al. Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. Lancet 1996; 347: 1432.
6. Leporrier M et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98 (8): 2319–25.
7. Rai K et al. A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia: a CALGB, SWOG, CTG/NCI-C and ECOG Intergroup study. Blood 1996; 88 (suppl. 1): 141a.
8. Flinn W. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000; 96 (1): 71–5.
9. O'Brien S et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 32: 6951–93.
10. Morrison A. Impact of Therapy With Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections in Patients With Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol 2001; 19 (Issue 16): 3611–21.
11. Keating M. Chronic lymphocytic leukemia: Scientific Advances and Clinical Developments. Marcel Dekker, New York, 1993.
12. Robertson L et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical pathologic, immunophenotypic and molecular analysis. Blood 1992; 80: 29.
13. Sorensen J et al. Treatment of refractory chronic lymphocytic leukemia (CLL) with fludarabine monophosphate (FAMP) under the group C protocol (Abstr) Proc ASCO 1992; 11: 264a.
14. Zinzani P et al. Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. Eur J Hematol 1993; 51: 93–7.
15. Hallek M, Schmitt B, Wilhelm M et al. and the German Chronic Lymphocytic Leukaemia Study Group. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol 2001; 114: 342–8.
16. Foran M et al. Multicenter Phase II Study of Fludarabine Phosphate for Patients With Newly Diagnosed Lymphoplasmacytoid Lymphoma, Waldenstrцm's Macroglobulinemia, and Mantle-Cell Lymphoma. J Clin Oncol 1999; 17 (Issue 2): 546.
17. Zinzani P et al. Randomized Trial of Fludarabine Versus Fludarabine and Idarubicin as Frontline Treatment in Patients With Indolent or Mantle-Cell Lymphoma. J Clin Oncol 2000; 18 (Issue 4): 773.
18. Solal-Celigny P et al. Phase II trial of fludarabine monophosphate as first-line therapy in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1996; 14: 514–9.
19. Decaudin D. Phase II trial of fludarabine monophosphate in patients with mantle- cell lymphomas. J Clin Oncol 1998; 16: 579–83.
20. Hochster S et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and long-term follow-up – a report from the Eastern Cooperative Oncology Group. J Clin Oncol 2000; 18 (Issue 5): 987.
21. McLaughlin P et al. Fludarabine, mitoxantrone and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 1996; 1262–8.
22. Velasquez W, McLaughlin P et al: ESHAP – An effective chemotherapy regimen in refractory and relapsing lymphoma: A4-year follow-up study. J Clin Oncol 1994; 12: 1169–76.

А.Б.Федоров,  О.А.Рукавицын

Главный военный клинический госпиталь им. Н.Н.Бурденко Министерства обороны РФ, гематологический центр